Rapporterte hendelser med Sutent ved metastatisk nyrekreft

Selekterte rapporterte hendelser fra registreringsstudien ved behandling av metastatisk nyrekreft1

* Listed are all treatment-related adverse events of interest and those occurring in at least 10% of patients in the sunitinib group. All severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
† The comparison between the sunitinib group and the interferon alfa group was significant (P<0.05) with the use ofFisher’s exact test applied to the sum of grade 3 and 4 adverse events. The significance of the comparison between treatment groups for “all grades” of adverse events is not shown.

For bivirkninger sett ved behandling av GIST og pNET se Sutent SPC

  1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib vs Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl Med 2007.356:115-124.